Sporos Bio is developing a novel and well differentiated TEAD1/4 inhibitor, SPR1. TEAD is a clinically validated target. Pre-clinical efficacy and safety data for SPR1 suggests a best-in-class agent in monotherapy across Hippo pathway altered cancers, well beyond mesothelioma and NF2 mutations. Specific utility has been demonstrated across squamous cell carcinomas. In combination with MAPK pathway inhibitors, SPR1 shows superior efficacy consistent with Hippo pathway activated resistance in genetically-altered cancers (i.e. treatment with KRAS, EGFR and FGFR inhibitors). SPR1 has completed 28 day GLP tox in dogs and 28 day GLP tox in rates is ongoing. Sporos Bio is looking for a partner to facilitate and accelerate development activities of our TEAD inhibitor and is open to out-licensing/partnership and or venture financing.